Starbloom Capital Research
Investment Thesis
Starbloom Capital describes itself as investing in breakthrough innovations in deep tech: longevity biotech, neuroAI, and emerging industries. Its tagline is "Illuminating the next frontiers." The firm partners with founders it describes as pushing the frontiers of science, technology, and human potential. The team presents itself as investors, operators, and scientists with deep roots in research, entrepreneurship, and frontier technology.
The firm grew out of the interests of its founder, James Fickel, an early Ethereum investor who used that capital to fund longevity and neuroscience research through the Amaranth Foundation (backing the Enigma Project, E11 Bio, Forest Neurotech, Impetus Grants, and the AFAR SuperAgers Cohort). Starbloom is the venture arm of that same worldview: science-led, long-horizon, and willing to back academic-founder companies.
Sector Focus
- Longevity and life sciences: therapeutics, protein sequencing, cell therapy, small molecules for age-related disease, diagnostics, and veterinary longevity
- NeuroAI and neurotechnology: brain foundation models, brain digital twins, and non-invasive neurostimulation
- Crypto: institutional infrastructure for Ethereum (Etherealize)
- Clean energy: next-generation perovskite solar (Swift Solar)
Biotech and neuroAI are the core; crypto and energy reflect the founder's background and a willingness to back other frontier technology.
Stage Focus
The site does not state a stage. Third-party data (CB Insights, PitchBook, Caplight, as reported in search snippets) shows seed and Series A deals, with at least one later round (Cognito Therapeutics Series C, March 2026). Stage preferences here are inferred and low confidence.
Check Size
Not disclosed on the site or in any source read. Check size fields are left empty.
Lead Tendency
Unknown. No source read states whether Starbloom leads or follows.
Recent Activity
CB Insights reports 21 investments, with the latest being a seed in Metamorphic around March 2026. Caplight lists Cognito Therapeutics (Series C, March 2026), 0xbow (seed, November 2025), Adaptyx Biosciences (seed, October 2025), and Bexorg (Series A, October 2025). These come from search snippets only, so only companies on the firm's own portfolio page were added to the portfolio. The firm's newsroom lists Swift Solar's $27M Series A (June 2024), a Bloomberg feature on Fickel's crypto-funded brain and longevity push (November 2024), a Bloomberg piece on Etherealize (January 2025), and Cognito's AD/PD 2025 data (March 2025). Fund size and fund status are not disclosed.
Portfolio Highlights
The portfolio page lists 13 featured investments, including Metamorphic (brain foundation models; founders include Andreas Tolias and Sophia Sanborn), Cognito Therapeutics (neurostimulation for Alzheimer's; Ed Boyden and Li-Huei Tsai), Bexorg (brain digital twins), Gordian Bio (age-related disease therapies), Loyal (canine longevity), Revel (enzymes reversing molecular damage), Cyclarity (atherosclerosis small molecules), Glyphic Bio (protein sequencing), LiFT (allogeneic neutrophil cell therapy), MagIC (point-of-care molecular diagnostics), Swift Solar (perovskite photovoltaics), and Etherealize (Ethereum for institutions). Many portfolio companies are spun out of academic labs with prominent scientist founders.
Team
- James Fickel, Founder and Managing Director: early Ethereum investor, founder of the Amaranth Foundation
- Kevin Liang, COO: former Chief of Staff to Mark Pincus, Head of Operations at Etherealize, ex-BCG and Citigroup, Harvard BA and Stanford MBA
- Jarod Rutledge, Director, Biotech Investments: Stanford PhD in Genetics, leads therapeutics, devices, techbio and diagnostics
- Joanne Peng, Director, NeuroAI Investments: Research Director at Amaranth, Thiel Fellow, Princeton CS
- Patrick Mineault, Director, NeuroAI Research: computational neuroscientist, ex-Google, Meta, and Mila, runs the neuroAI archive Substack
- Emilio Aguilar Rosenthal, Manager, Data Science and Analytics
Decision Process
Not disclosed. The team is small with sector-specific directors (biotech, neuroAI), which suggests a partnership-style process, but this is not stated.
Founder Preferences
Scientist-founders and research-lab spinouts with a path to improving human health and capability. Portfolio founders frequently include professors and PhDs.
Geographic Focus
Offices in New York and San Francisco. No stated geographic restriction; the portfolio appears US-centered. Contact: [email protected].